Myeloid-derived suppressor cells in glioma.
Glioblastoma is the most prevalent form of gliomas with high aggressive nature and high recurrence. Despite aggressive therapy, including surgery, chemotherapy and radiotherapy, median patient survival is only about 15 months. Hence, developing novel and efficient therapies seem urgent. Many fields have begun their work in preclinical studies but gained limited success in clinical phases. One of the most notable reasons is tumor-induced immunosuppression. In recent decade, efforts to dissect this immunosuppressive network have been done vastly. In a number of malignancies such as glioma, myeloid-derived suppressor cells (MDSCs) have been shown to infiltrate malignant tissues having critical role in the network. Many studies, most of them on lab models, were conducted to understand how MDSCs take part in immunosuppression. Here, we reviewed MDSC relations with other immunocellular components like T cell and natural killer cell.
Research Center for Immunodeficiencies, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran.
Masoud
M
Mirghorbani
Stefaan
S
Van Gool
Nima
N
Rezaei
D000818:Animals; D064987:Cell- and Tissue-Based Therapy / Q000379:methods; D005910:Glioma / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007165:Immunosuppression Therapy; D022423:Myeloid Cells / Q000166:cytology* / Q000276:immunology / Q000637:transplantation; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology